Current Oncology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data.  28:1153-1160. 2021
• Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report.  28:390-395. 2021
• Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report.  28:226-232. 2020
• Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment.  27:607-613. 2020
• First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma.  27:632-644. 2020
• Implementing Changes to a Residency Program Curriculum before Competency-Based Medical Education: A Survey of Canadian Medical Oncology Program Directors.  27:614-620. 2020
• Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations.  27:270-274. 2020
• Improving Formative Assessments in Canadian Medical Oncology Residency Training.  27:524-525. 2020
• Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists.  27:263-269. 2020
• Age-Dependent Increased Odds of Cardiovascular Risk Factors in Cancer Survivors: Canadian Longitudinal Study on Aging Cohort.  27:368-376. 2020
• Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma.  27:204-214. 2020
• Inflammatory Markers as Prognostic Factors of Recurrence in Advanced-Stage Squamous Cell Carcinoma of the Head and Neck.  27:135-141. 2020
• A Catalyst for Transforming Health Systems and Person-Centred Care: Canadian National Position Statement on Patient-Reported Outcomes.  27:90-99. 2020
• Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer.  27:146-155. 2020
• Immuno-Oncology—The New Paradigm of Lung Cancer Treatment.  27:78-86. 2020
• Organizational Guidance for the Care of Patients with Head-and-Neck Cancer in Ontario.  27:115-122. 2020
• Complex Surgery and Perioperative Systemic Therapy for Genitourinary Cancer of the Retroperitoneum.  27:34-42. 2020
• Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.  27:43-52. 2020
• The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?.  27:10-11. 2020
• Trends in Survival Based on Treatment Modality in Patients with Pancreatic Cancer: A Population-Based Study.  27:1-8. 2020
• OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing.  26:618-623. 2019
• An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction.  26:240-246. 2019
• Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective.  26:551-557. 2019
• Evolution of Adolescent and Young Adult Oncology in Canada.  26:228-233. 2019
• Lessons Learned from a Cancer Knowledge Translation Grants Program: Results of an Evaluation.  26:272-284. 2019
• Psychedelics for Psychological and Existential Distress in Palliative and Cancer Care.  26:225-226. 2019
• Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario.  26:247-252. 2019
• Incidence of Radionecrosis in Single-Fraction Radiosurgery Compared with Fractionated Radiotherapy in the Treatment of Brain Metastasis.  26:328-333. 2019
• Initial Management of Small-Cell Lung Cancer (limited- and Extensive-Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy: A Systematic Review.  26:372-384. 2019
• Renal Cell Carcinoma in the Canadian Indigenous Population.  26:367-371. 2019
• Surgery after Chemoradiotherapy in Patients with Stage III (n2 or N3, Excluding T4) Non-Small-Cell Lung Cancer: A Systematic Review.  26:398-404. 2019
• Establishing Funding Rates for Colonoscopy and Gastroscopy Procedures in Ontario.  26:98-101. 2019
• Surgical Attitudes toward Preoperative Breast Magnetic Resonance Imaging in Women with Early-Stage Breast Cancer.  26:194-201. 2019
• Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer.  26:81-93. 2019
• Integrating Primary Care Providers through the Seasons of Survivorship.  26:48-54. 2019
• A Little Help from My Friends: Social Support in Palliative Rehabilitation.  25:358-365. 2018
• Moving Research Into Practice: Summary Report of the Ex/Cancer Meeting on Physical Activity, Exercise, and Rehabilitation in Oncology.  25:615-621. 2018
• Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort.  25:384-392. 2018
• Survival of Patients with Subglottic Squamous Cell Carcinoma.  25:569-575. 2018
• Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting.  25:576-584. 2018
• Canadian Evidence-Based Guideline for the First-Line Treatment of Chronic Lymphocytic Leukemia.  25:461-474. 2018
• Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer.  25:317-328. 2018
• Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites.  25:300-306. 2018
• Is There a Role for Adjuvant Therapy After Surgery in “High Risk for Recurrence” Kidney Cancer? an Update on Current Concepts.  25:444-453. 2018
• Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer.  25:490-498. 2018
• Treatment Algorithm in Cancer-Associated Thrombosis: Canadian Expert Consensus.  25:329-337. 2018
• Engaging Cancer Patients in Clinical Practice Guideline Development: A Pilot Study.  25:250-256. 2018
• Anastomosing Hemangioma of the Kidney: Radiologic and Pathologic Distinctions of a Kidney Cancer Mimic.  25:220-223. 2018
• Antiangiogenic Therapies in Non-Small-Cell Lung Cancer.  25:45-58. 2018
• Clinical Practice Guidelines in Breast Cancer.  25:151-160. 2018
• Comprehensive Metastatic Lung Cancer Care Must Include Palliative Care.  25:192-193. 2018
• Connecting People with Cancer to Physical Activity and Exercise Programs: A Pathway to Create Accessibility and Engagement.  25:149-162. 2018
• Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer.  25:73-82. 2018
• Feasibility of Assessing Patient Health Benefits and Incurred Costs Resulting from Early Dysphagia Intervention during and Immediately after Chemoradiotherapy for Head-and-Neck Cancer.  24:466-476. 2017
• Identifying Barriers to Accrual in Radiation Oncology Randomized Trials.  24:524-530. 2017
• Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline.  24:540-546. 2017
• Staging and Surgical Approaches in Gastric Cancer: A Clinical Practice Guideline.  24:324-331. 2017
• Systemic Therapy in Incurable Gastroenteropancreatic Neuroendocrine Tumours: A Clinical Practice Guideline.  24:249-255. 2017
• Palliative Care as a Public Health Issue: Understanding Disparities in Access to Palliative Care for the Homeless Population Living in Toronto, Based on a Policy Analysis.  24:187-191. 2017
• Quality of Life for Patients Surviving Cancer: Are We Moving Ahead?.  24:151-152. 2017
• Challenges and Insights in Implementing Coordinated Care between Oncology and Primary Care Providers: A Canadian Perspective.  24:120-123. 2017
• Comparative Survival in Patients with Brain Metastases from Non-small-Cell Lung Cancer Treated before and after Implementation of Radiosurgery.  24:146-151. 2017
• Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario.  24:103-110. 2017
• Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective.  24:111-119. 2017
• Multigene Expression Profile Testing in Breast Cancer: Is There a Role for Family Physicians?.  24:95-102. 2017
• Systemic Therapy in the Curative Treatment of Head-and-Neck Squamous Cell Cancer: Cancer Care Ontario Clinical Practice Guideline.  24:157-162. 2017
• Uptake of a 21-Gene Expression Assay in Breast Cancer Practice: Views of Academic and Community-Based Oncologists.  24:138-145. 2017
• A Canadian Perspective on the Subcutaneous Administration of Rituximab in Non-Hodgkin Lymphoma.  24:33-39. 2017
• Does Adjuvant Radiation Therapy Benefit Women with Small Mammography-Detected Breast Cancers?.  24:28-32. 2017
• Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario.  24:50-54. 2017
• Guideline for Radiotherapy with Curative Intent in Patients with Early-Stage Medically Inoperable Non-Small-Cell Lung Cancer.  24:44-49. 2017
• Introducing Dr. Matthew Seftel.  24:7-7. 2017
• Moving Guidelines into Action: A Report from Cancer Care Ontario’s Event Let’s Get Moving: Exercise and Rehabilitation for Cancer Patients.  24:65-74. 2017
• Adjuvant Systemic Chemotherapy for Stages II and III Colon Cancer after Complete Resection: A Clinical Practice Guideline.  23:418-424. 2016
• Early Palliative Care: Taking Ownership and Creating the Conditions.  23:367-370. 2016
• Clinical Surveillance Compared with Clinical and Magnetic Resonance Imaging Surveillance for Brain Metastasis: A Feasibility Survey.  23:356-360. 2016
• Follow-Up Care for Survivors of Lymphoma Who Have Received Curative-Intent Treatment.  23:499-513. 2016
• Follow-Up of Patients Who Are Clinically Disease-Free after Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation.  23:343-350. 2016
• Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy: A Clinical Practice Guideline.  23:280-285. 2016
• Fee-for-Service Cancer Rehabilitation Programs Improve Health-Related Quality of Life.  23:233-240. 2016
• Approach to Biomarker Testing: Perspectives from Various Specialties.  23:178-183. 2016
• Can the Referring Surgeon Enhance Accrual of Breast Cancer Patients to Medical and Radiation Oncology Trials? The Enhance Study.  23:276-279. 2016
• Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer.  23:196-200. 2016
• Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration.  23:179-187. 2016
• Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists.  23:184-195. 2016
• Accrual of Adolescents and Young Adults with Cancer to Clinical Trials.  23:81-85. 2016
• Collaborative Case Conferences in Rectal Cancer: Case Series in a Tertiary Care Centre.  23:138-143. 2016
• Follow-Up for Cervical Cancer: A Program in Evidence-Based Care Systematic Review and Clinical Practice Guideline Update.  23:109-118. 2016
• Cost Trajectories for Cancer Patients.  23:64-75. 2016
• Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging Therapies in the Treatment of Pancreatic, Rectal, and Colorectal Cancers.  23:52-55. 2016
• Temporal Association between Home Nursing and Hospital Costs at End of Life in Three Provinces.  23:42-51. 2016
• Worth His Weight in ....  22:372-373. 2015
• Are Patients Receiving the Right Care in the Right Place at the Right Time?.  22:315-316. 2015
• Quality of End-of-Life Cancer Care in Canada: A Retrospective Four-Province Study Using Administrative Health Care Data.  22:341-355. 2015
• Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?.  22:272-278. 2015
• The Optimal Organization of Gynecologic Oncology Services: A Systematic Review.  22:282-293. 2015
• The Organization of Colposcopy Services in Ontario: Recommended Framework.  22:287-296. 2015
• Views of Family Physicians about Survivorship Care Plans to Provide Breast Cancer Follow-Up Care: Exploration of Results from a Randomized Controlled Trial.  22:252-259. 2015
• Systemic Therapy for Recurrent, Persistent, or Metastatic Cervical Cancer: A Clinical Practice Guideline.  22:211-219. 2015
• Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review.  22:183-215. 2015
• Consensus Statement: The 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5–6, 2014.  22:113-123. 2015
• Erratum: Tumour Inflammatory Response: Adding Fuel to the Fire?.  22:133-133. 2015
• Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms.  22:100-112. 2015
• Secular Trends in the Survival of Patients with Laryngeal Carcinoma, 1995–2007.  22:85-99. 2015
• A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and Beyond.  22:43-53. 2015
• Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline.  22:54-66. 2015
• Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations.  22:49-59. 2015
• Safe Handling of Cytotoxics: Guideline Recommendations.  22:27-37. 2015
• Tumour Inflammatory Response: Adding Fuel to the Fire?.  22:7-9. 2015
• A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults.  21:234-250. 2014
• A Systematic Review of Active Treatment Options in Patients with Desmoid Tumours.  21:613-629. 2014
• Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations.  21:573-603. 2014
• Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor.  21:564-572. 2014
• Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline.  21:642-649. 2014
• Access to Personalized Medicine: Factors Influencing the Use and Value of Gene Expression Profiling in Breast Cancer Treatment.  21:426-433. 2014
• Metastatic Renal Cell Carcinoma without Evidence of a Primary Renal Tumour.  21:521-524. 2014
• Utilization of Stereotactic Ablative Radiotherapy in the Management of Oligometastatic Disease.  21:115-117. 2014
• Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus.  21:265-309. 2014
• Patients’ Perceptions of Gene Expression Profiling in Breast Cancer Treatment Decisions.  21:203-211. 2014
• Practice and Documentation of Palliative Sedation: A Quality Improvement Initiative.  21:100-103. 2014
• Rasch analysis of the Edmonton Symptom Assessment System and research implications.  21:186-194. 2014
• A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events.  21:35-42. 2014
• Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.  21:96-96. 2014
• Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence.  21:44-50. 2014
• A Prospective Evaluation of an Interdisciplinary Nutrition–Rehabilitation Program for Patients with Advanced Cancer.  20:310-318. 2013
• An Interprofessional Palliative Care Oncology Rehabilitation Program: Effects on Function and Predictors of Program Completion.  20:301-309. 2013
• Outcomes of her2-positive Early-Stage Breast Cancer in the Trastuzumab Era: A Population-Based Study of Canadian Patients.  20:539-545. 2013
• The Association between Malnutrition and Psychological Distress in Patients with Advanced Head-and-Neck Cancer.  20:554-560. 2013
• Canadian Integrative Oncology Research Priorities: Results of a Consensus-Building Process.  20:289-299. 2013
• Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases.  20:300-306. 2013
• Surgical Margins and Handling of Soft-Tissue Sarcoma in Extremities: A Clinical Practice Guideline.  20:247-254. 2013
• A Comparison of Patient Knowledge of Clinical Trials and Trialist Priorities.  20:193-205. 2013
• Liver Resection for Colorectal Cancer Metastases.  20:255-265. 2013
• Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience.  20:223-232. 2013
• The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care..  20:e57-e58. 2013
• Alignment of Practice Guidelines with Targeted-therapy Drug Funding Policies in Ontario.  20:21-33. 2013
• Consensus Recommendations for Cancer Rehabilitation: Research and Education Priorities.  20:64-69. 2013
• Endocrine Therapy for Postmenopausal Women with Hormone Receptor–Positive her2–Negative Advanced Breast Cancer after Progression or Recurrence on Nonsteroidal Aromatase Inhibitor Therapy: A Canadian Consensus Statement.  20:48-61. 2013
• Response to: What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?.  19:502-502. 2012
• Improving Referral of Patients for Consideration of Adjuvant Chemotherapy after Surgical Resection of Lung Cancer.  19:422-427. 2012
• Bone-Targeted Agents and Skeletal-Related Events in Breast Cancer Patients with Bone Metastases: The State of the Art.  19:259-268. 2012
• Excision of the Primary Tumour in Patients with Metastatic Breast Cancer: A Clinical Dilemma.  19:270-279. 2012
• Management of a Suspicious Adnexal Mass: A Clinical Practice Guideline.  19:244-257. 2012
• Casting Stones and Casting Aspersions: Let’s Not Lose Sight of the Main Issues in the Euthanasia Debate.  19:139-142. 2012
• Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study.  19:129-135. 2012
• Fertility Risk Discussions in Young Patients Diagnosed with Colorectal Cancer.  19:155-159. 2012
• The Importance of Multidisciplinary Team Management of Patients with Non-Small-Cell Lung Cancer.  19:7-15. 2012
• Extending Neoadjuvant Care through Multi-Disciplinary Collaboration: Proceedings from the Fourth Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer.  19:106-114. 2012
• What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?.  19:60-66. 2012
• A Call for Action in Survivorship Research and Care.  19:16-20. 2012
• Challenges in Knowledge Translation: The Early Years of Cancer Care Ontario’s Program in Evidence-Based Care.  19:27-35. 2012
• Fine-Needle Sspiration Biopsy versus Core-Needle Biopsy in Diagnosing Lung Cancer: A Systematic Review.  19:16-27. 2012
• Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis.  19:9-15. 2012
• Phenytoin Toxicity in a Patient Receiving 5-Fluorouracil–Based Chemotherapy for Metastatic Colorectal Cancer.  18:264-265. 2011
• Survivorship Services for Adult Cancer Populations: A Pan-Canadian Guideline.  18:265-281. 2011
• Establishing a Multicentre Clinical Research Network: Lessons Learned.  18:243-249. 2011
• Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.  18:S11-S19. 2011
• Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.  18:S5-S10. 2011
• Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer.  18:180-184. 2011
• Prophylactic Feeding Tubes for Patients with Locally Advanced Head-and-Neck Cancer Undergoing Combined Chemotherapy and Radiotherapy—Systematic Review and Recommendations for Clinical Practice.  18:191-201. 2011
• cml Biology for the Clinician in 2011: Six Impossible Things to Believe before Breakfast on the Way to Cure.  18:185-190. 2011
• Improving Cancer Control in Canada One Case at a Time: The “knowledge Translation in Cancer” Casebook.  18:76-83. 2011
• Legalizing Euthanasia or Assisted Suicide: The Illusion of Safeguards and Controls.  18:38-45. 2011
• Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21.  18:84-90. 2011
• A Comparative Analysis of Monthly Out-of-Pocket Costs for Patients with Breast Cancer as Compared with Other Common Cancers in Ontario, Canada.  18:681-681. 2011
• Terry Fox's legacy: a case for translational research.  17:262-263. 2010
• Cancer Nutrition Rehabilitation Program: The Role of Social Work.  17:12-17. 2010
• Terry Fox’s Legacy: A Case for Translational Research.  17:2-3. 2010
• Current Management of Castrate-Resistant Prostate Cancer.  17:72-79. 2010
• Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality.  17:20-33. 2010
• Optimizing the management of HER2-positive early breast cancer: the clinical reality.  17:154-167. 2010
• Follow-Up for Women after Treatment for Cervical Cancer.  17:65-69. 2010
• Estimating the National Wage Loss from Cancer in Canada.  17:40-49. 2010
• Feasibility of Administering Zoledronic Acid in Palliative Patients Being Cared for in the Community: Results of a Pilot Study.  17:69-74. 2010
• Current management of castrate-resistant prostate cancer.  17. 2010
• Ductal Carcinoma In Situ in a 25-Year-Old Man Presenting with Apparent Unilateral Gynecomastia.  17:133-137. 2010
• Cancer Diagnostic Assessment Programs: Standards for the Organization of Care in Ontario.  16:29-41. 2009
• Clinician-patient communication: evidence-based recommendations to guide practice in cancer.  16:398-405. 2009
• Clinician–Patient Communication: Evidence-Based Recommendations to Guide Practice in Cancer.  16:42-49. 2009
• Generalizability of Toxicity Data from Oncology Clinical Trials to Clinical Practice: Toxicity of Irinotecan-Based Regimens in Patients with Metastatic Colorectal Cancer.  16:13-20. 2009
• ¹³¹I-tositumomab in lymphoma.  16:32-47. 2009
• I-Tositumomab in lymphoma..  16:32-47. 2009
• The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers.  16:48-57. 2009
• The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer.  16:25-35. 2009
• The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.  16:235-245. 2009
• Novel developments in angiogenesis cancer therapy.  16:191-195. 2009
• Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma..  16 Suppl 1:S60-S66. 2009
• Hormone replacement therapy and outcome for women with non-small cell lung cancer: can an association be confirmed?.  16:21-25. 2009
• Novel Developments in Angiogenesis Cancer Therapy.  16:50-54. 2009
• Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents.  16:40-44. 2009
• A Framework for the Organization and Delivery of Systemic Treatment.  16:4-15. 2009
• Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.  16:S62-S68. 2009
• I-131-Tositumomab in lymphoma.  16:32-47. 2009
• Inhibition of mTOR in kidney cancer.  16:S35-S41. 2009
• The Role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic, and Recurrent Non-Small-Cell Lung Cancer: A Canadian National Consensus Statement.  16:27-48. 2009
• Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel.  15:44-47. 2008
• Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel..  15:298-301. 2008
• The Colon Health and Life-Long Exercise Change (CHALLENGE) trial (CO.21).  15:279-285. 2008
• The Colon Health and Life-Long Exercise Change trial: A randomized trial of the National Cancer Institute of Canada Clinical Trials Group.  15:8-16. 2008
• The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group.  15:262-270. 2008
• Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group.  15:179-184. 2008
• Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the National Cancer Institute of Canadia Clinical Trials Group.  15:14-19. 2008
• Healing and Survivorship: What Makes a Difference?.  15:185-187. 2008
• Healing and survivorship: What makes a difference?.  15:20-22. 2008
• How Do We Evaluate Outcome in an Integrative Oncology Program?.  15:78-82. 2008
• Integrative Cancer Care in a US Academic Cancer Centre: The Memorial Sloan–Kettering Experience.  15:108-108. 2008
• Integrative Oncology: A Canadian and International Perspective.  15:s71-s73. 2008
• Research and Regulatory Issues for Integrative Oncology.  15:107-108. 2008
• Cancer Nutrition and Rehabilitation—Its Time Has Come!.  15:117-122. 2008
• Chinese Medicine and Biomodulation in Cancer Patients—Part One.  15:42-48. 2008
• Chinese Medicine and Biomodulation in Cancer Patients—Part Two.  15:78-78. 2008
• Research and regulatory issues for integrative oncology.  15:S53-S63. 2008
• Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer.  14:195-208. 2007
• Treatment of Depression in Cancer Patients.  14:180-188. 2007
• Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185.  14:154-161. 2007
• Alemtuzumab in Chronic Lymphocytic Leukemia.  14:96-109. 2007
• A Tale of Two Time Periods: Ovarian Cancer Trends in Ontario.  14:57-60. 2007
• Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The National Cancer Institute of Canada Clinical Trials Group MY.11 Trial.  14:61-65. 2007
• Massage Therapy for Cancer Patients: A Reciprocal Relationship between Body and Mind.  14:45-56. 2007
• Radiofrequency Ablation and Cryoablation of Renal Tumours.  14:34-38. 2007
• Cross-border referral for early breast cancer: an analysis of radiation fractionation patterns..  13:124-129. 2006
• Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review..  13:81-93. 2006
• Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2..  13:99-107. 2006
• Promoting best gynecologic oncology practice: a role for the Society of Gynecologic Oncologists of Canada..  13:94-98. 2006
• Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1..  13:14-26. 2006
• Role of bisphosphonates in the management of skeletal complications in patients with multiple myeloma.  12:3-17. 2005
• Psychological, physical, social and economic impact of traveling great distances for cancer treatment.  12:1-7. 2005
• Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer.  11:41-52. 2004
• Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns.  11:68-71. 2004
• Role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer.  10:146-160. 2003
• Role of octreodite in the management of patients with cancer.  10:161-179. 2003
• Role of taxanes in the management of metastatic breast cancer.  10:68-83. 2003
• Use of gemcitabine in non-small-cell lung cancer.  10:3-26. 2003
• Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines.  9:7-12. 2002
• The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer.  8:50-59. 2001
• Use of irinotecan combined with 5-fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer.  8:60-68. 2001
• Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck.  8:16-27. 2001
• Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck.  8:6-15. 2001
• Treatment of locally advanced squamous cell carcinoma of the head and neck: A summary and overview.  8:3-5. 2001
• Drug therapy for chronic myeloid leukaemia.  7:229-241. 2000
• Participation patterns of oncologists in the development of clinical practice guidelines.  7:252-257. 2000
• The use of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer and methods of assessing HER2/neu status - An evidence summary.  7:242-251. 2000
• Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer.  7:149-161. 2000
• Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients.  7:136-148. 2000
• Use of capecitabine in stage IV breast cancer: An evidence summary.  7:84-90. 2000
• Use of irinotecan in secondline treatment of metastatic colorectal carcinoma.  7:29-36. 2000
• 'Two solitudes' or 'A mouse in bed with two elephants'.  7:3-4. 2000
• Use of vinorelbine in stage IV breast cancer: An evidence summary.  7:24-28. 2000
• Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer.  7:98-109. 2000
• Optimum radiation fractionation for T1 N0 glottic carcinoma.  7:91-97. 2000
• The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer.  7:162-172. 2000
• Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab.  6:131-137. 1999
• Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients.  6:155-160. 1999
• Use of biphosphonates in patients with bone metastases from breast cancer.  6:144-154. 1999
• Use of rituximab in the treatment of lymphoma: An evidence summary.  6:228-235. 1999
• The role of fludarabine in intermediate- and high-risk chronic lymphocytic leukaemia.  6:90-102. 1999
• Humanized antibodies for cancer therapy. Part 1: Humanizing mouse antibodies.  6:74-77. 1999
• The role of adjuvant systemic therapy in node-negative breast cancer.  6:78-89. 1999
• Predictors of intention to act: High-school students and cervical screening.  6:36-42. 1999
• New initiatives in the management of recurrent breast cancer.  5:188-194. 1998
• Bisphosphonates for bone metastases in breast cancer patients: Trial design issues and evaluation of published studies.  5:181-187. 1998
• Bone metastases: A review of their pathogenesis.  5:114-118. 1998
• Recent reports in breast cancer.  5:143-147. 1998
• High-Grade Glioma Management and Response Assessment—Recent Advances and Current Challenges.  23:383-391.
• Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? 2009
• The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake 2009
• The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake 2008
• 22nd Annual San Antonio Breast Cancer Symposium, December 8-11, 1999 1999
• 35th Annual Meeting of the American Society of Clinical Oncology: What's new in breast cancer 1999
• 21st Annual San Antonio Breast Cancer Symposium, December 12-15, 1998 1999
• 20th annual San Antonio Breast Cancer Symposium, December 3-6, 1997 1998
• International St. Gallen conference: Adjuvant therapy of primary breast cancer, February 25-28, 1998 1998

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• Oncology & Carcinogenesis (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 1198-0052

Electronic International Standard Serial Number (EISSN)

• 1198-0052
• 1718-7729